Open AccessHarm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men
Author(s) -
Spyridon P. Basourakos,
Roman Gulati,
Randy Vince,
Daniel E. Spratt,
Patrick Lewicki,
Alexander J. Hill,
Yaw A. Nyame,
Jennifer Cullen,
Sarah C. Markt,
Christopher E. Barbieri,
Jim C. Hu,
Erika S. Trapl,
Jonathan Shoag
Publication year - 2022
Publication title -
nejm evidence
Language(s) - English
Resource type - Journals
ISSN - 2766-5526
DOI - 10.1056/evidoa2200031
Subject(s) - overdiagnosis , medicine , prostate cancer , prostate cancer screening , epidemiology , incidence (geometry) , population , demography , relative risk , cancer , prostate , gynecology , prostate specific antigen , confidence interval , environmental health , physics , sociology , optics
Prostate-specific antigen screening has profoundly affected the epidemiology of prostate cancer in the United States. Persistent racial disparities in outcomes for Black men warrant re-examination of the harms of screening relative to its cancer-specific mortality benefits in this population.